BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 16759774)

  • 21. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
    Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transplant strategies for myelodysplastic syndrome.
    McCarty J
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):559-72. PubMed ID: 15494294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of HLA in hematopoietic SCT.
    Nowak J
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S71-6. PubMed ID: 18978750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic stem cell transplantation for myelodysplastic syndromes in children: a report from the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Díaz-Heredia C; Badell I; Bureo E; Gómez P; Martínez A; Verdeguer A; Pérez-Hurtado JM; Fernández-Delgado R; González-Vicent M; Maldonado MS
    Pediatr Hematol Oncol; 2009; 26(5):345-55. PubMed ID: 19579081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Allogeneic hematopoietic stem cell transplantation].
    Mohty M
    Rev Prat; 2008 Dec; 58(19):2111-22. PubMed ID: 19213539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donor buffy coat infusions for a patient with myelodysplastic syndrome who relapsed following allogeneic bone marrow transplantation.
    Tsuzuki M; Maruyama F; Kojima H; Ezaki K; Hirano M
    Bone Marrow Transplant; 1995 Sep; 16(3):487-9. PubMed ID: 8535326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
    Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The A-B-C of haematopoietic stem cell transplantation.
    Rafeah NT; Fadilah SA
    Med J Malaysia; 2009 Mar; 64(1):94-100; quiz 101. PubMed ID: 19852335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors.
    Koh LP; Rizzieri DA; Chao NJ
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1249-67. PubMed ID: 17950913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases.
    Bradley MB; Satwani P; Baldinger L; Morris E; van de Ven C; Del Toro G; Garvin J; George D; Bhatia M; Roman E; Baxter-Lowe LA; Schwartz J; Qualter E; Hawks R; Wolownik K; Foley S; Militano O; Leclere J; Cheung YK; Cairo MS
    Bone Marrow Transplant; 2007 Oct; 40(7):621-31. PubMed ID: 17660841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood.
    Strahm B; Locatelli F; Bader P; Ehlert K; Kremens B; Zintl F; Führer M; Stachel D; Sykora KW; Sedlacek P; Baumann I; Niemeyer CM
    Bone Marrow Transplant; 2007 Aug; 40(4):329-33. PubMed ID: 17589538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haematopoietic stem cell transplantation: current status.
    Kumar L
    Natl Med J India; 2007; 20(3):128-37. PubMed ID: 17867617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haematopoeitic cell transplantation for Fanconi anaemia - when and how?
    MacMillan ML; Wagner JE
    Br J Haematol; 2010 Apr; 149(1):14-21. PubMed ID: 20136826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease.
    Davies JK; Taussig DC; Oakervee H; Davies AJ; Agrawal SG; Gribben JG; Lister TA; Cavenagh JD
    J Clin Oncol; 2006 May; 24(14):e23-5. PubMed ID: 16682729
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.